TWI633122B - 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白 - Google Patents

針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白 Download PDF

Info

Publication number
TWI633122B
TWI633122B TW105124816A TW105124816A TWI633122B TW I633122 B TWI633122 B TW I633122B TW 105124816 A TW105124816 A TW 105124816A TW 105124816 A TW105124816 A TW 105124816A TW I633122 B TWI633122 B TW I633122B
Authority
TW
Taiwan
Prior art keywords
pcsk9
antigen
group
binding protein
seq
Prior art date
Application number
TW105124816A
Other languages
English (en)
Chinese (zh)
Other versions
TW201716444A (zh
Inventor
賽門 傑克森
奈吉爾 佩爾漢 柯林頓 沃克
德里克 艾凡 派普爾
單倍
沈文彥
陳志怡
恰德威克 泰倫斯 金
蘭德爾 羅伯特 凱特肯
克里斯多夫 梅琳
特麗莎 阿拉扎斯 凱洛貝
琼 曹
Original Assignee
安美基公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39951467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI633122(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 安美基公司 filed Critical 安美基公司
Publication of TW201716444A publication Critical patent/TW201716444A/zh
Application granted granted Critical
Publication of TWI633122B publication Critical patent/TWI633122B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
TW105124816A 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白 TWI633122B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US95766807P 2007-08-23 2007-08-23
US60/957,668 2007-08-23
US896507P 2007-12-21 2007-12-21
US61/008,965 2007-12-21
US1063008P 2008-01-09 2008-01-09
US61/010,630 2008-01-09
US8613308P 2008-08-04 2008-08-04
US61/086,133 2008-08-04

Publications (2)

Publication Number Publication Date
TW201716444A TW201716444A (zh) 2017-05-16
TWI633122B true TWI633122B (zh) 2018-08-21

Family

ID=39951467

Family Applications (7)

Application Number Title Priority Date Filing Date
TW105124816A TWI633122B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW111138485A TWI890005B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW107117443A TWI799416B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶9型之抗原結合蛋白
TW103110948A TWI675847B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW097132236A TWI441833B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW103110947A TWI675846B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW103110949A TWI675848B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白

Family Applications After (6)

Application Number Title Priority Date Filing Date
TW111138485A TWI890005B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW107117443A TWI799416B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶9型之抗原結合蛋白
TW103110948A TWI675847B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW097132236A TWI441833B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW103110947A TWI675846B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
TW103110949A TWI675848B (zh) 2007-08-23 2008-08-22 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白

Country Status (42)

Country Link
US (27) US8030457B2 (enExample)
EP (3) EP2215124B9 (enExample)
JP (7) JP5441905B2 (enExample)
KR (9) KR101702194B1 (enExample)
CN (8) CN112409489A (enExample)
AR (1) AR068011A1 (enExample)
AU (1) AU2008288791B2 (enExample)
BR (2) BRPI0816117B8 (enExample)
CA (1) CA2696252C (enExample)
CL (1) CL2008002495A1 (enExample)
CO (1) CO6230997A2 (enExample)
CR (1) CR11328A (enExample)
CY (3) CY1117940T1 (enExample)
DE (2) DE202008018562U1 (enExample)
DK (2) DK2215124T4 (enExample)
EA (1) EA032106B1 (enExample)
ES (3) ES2573258T5 (enExample)
FI (2) FI3666797T3 (enExample)
FR (1) FR16C0025I2 (enExample)
HR (2) HRP20230503T3 (enExample)
HU (4) HUE062493T2 (enExample)
IL (5) IL317213A (enExample)
JO (1) JOP20080381B1 (enExample)
LT (3) LT3666797T (enExample)
LU (2) LU93096I2 (enExample)
MA (1) MA31978B1 (enExample)
MX (3) MX375117B (enExample)
MY (3) MY199053A (enExample)
NL (1) NL300818I2 (enExample)
NO (3) NO2016010I1 (enExample)
NZ (1) NZ584101A (enExample)
PE (8) PE20131400A1 (enExample)
PH (2) PH12013502285B1 (enExample)
PL (2) PL2215124T5 (enExample)
PT (1) PT3666797T (enExample)
RS (2) RS54756B2 (enExample)
SG (2) SG10201710183TA (enExample)
SI (2) SI2215124T2 (enExample)
TN (1) TN2010000063A1 (enExample)
TW (7) TWI633122B (enExample)
UA (1) UA127402C2 (enExample)
WO (1) WO2009026558A1 (enExample)

Families Citing this family (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof
SG171676A1 (en) * 2006-05-11 2011-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2245039A4 (en) * 2008-01-31 2012-06-06 Alnylam Pharmaceuticals Inc OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
ES2808660T3 (es) 2008-08-04 2021-03-01 Amgen Inc Proteínas de unión a antígeno para proproteína convertasa subtilisina kexina tipo 9 (PCSK9)
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
EP2442792A4 (en) * 2009-06-15 2015-12-23 Alnylam Pharmaceuticals Inc TESTING GENE PCSK9 LIPID-FORMULATED DSRNA
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
WO2011037791A1 (en) * 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
JP2013509591A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｐｃｓｋ９イムノアッセイ
IN2012DN03824A (enExample) * 2009-10-30 2015-08-28 Merck Sharp & Dohme
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US20130058891A1 (en) 2010-01-12 2013-03-07 Jay K. Kolls Kexin-Derived Vaccines to Prevent or Treat Fungal Infections
US9181538B1 (en) 2010-01-12 2015-11-10 Karen A. Norris Kexin-based vaccines to prevent or treat fungal infections
CN105218674A (zh) * 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
HRP20180959T1 (hr) * 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
EP2650016A1 (en) * 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
EP2673302A1 (en) * 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
JP6081714B2 (ja) * 2011-04-28 2017-02-15 株式会社ビー・エム・エル 高コレステロール血症と動脈硬化の検出方法
EP3421591B1 (en) 2011-04-28 2023-09-27 The Board of Trustees of the Leland Stanford Junior University Identification of polynucleotides associated with a sample
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012170607A2 (en) * 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
MX340498B (es) 2011-06-30 2016-07-11 Chugai Pharmaceutical Co Ltd Polipeptido heterodimerizado.
HK1202804A1 (en) * 2011-07-14 2015-10-09 辉瑞公司 Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
CA2848201C (en) * 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
EP3335747B1 (en) 2011-10-14 2021-04-07 Amgen Inc. Injector and method of assembly
US20140228539A1 (en) * 2011-10-21 2014-08-14 Tanvex Biologics Corp. Separation of acetylated proteins from unacetylated proteins
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
CA2870126C (en) 2012-04-09 2020-10-27 Daiichi Sankyo Company, Limited Anti-fgfr2 antibody
US9321681B2 (en) * 2012-04-27 2016-04-26 United States Gypsum Company Dimensionally stable geopolymer compositions and method
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2013170367A1 (en) * 2012-05-17 2013-11-21 The University Of British Columbia Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
ES2552371T3 (es) 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
RU2015101113A (ru) * 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
HUE035887T2 (en) 2012-12-05 2018-05-28 Alnylam Pharmaceuticals Inc PCSK9 iRNA preparations and methods for their use
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
US10287317B2 (en) * 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
JP2016514668A (ja) * 2013-03-15 2016-05-23 アムジエン・インコーポレーテツド プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
EP2976117B1 (en) 2013-03-22 2020-12-30 Amgen Inc. Injector and method of assembly
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
JP6417118B2 (ja) * 2013-05-31 2018-10-31 株式会社ビー・エム・エル Ｐｃｓｋ９測定用標準物質
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CN111920954A (zh) 2013-06-07 2020-11-13 再生元制药公司 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
AU2013396206B2 (en) * 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
CN106062003A (zh) 2013-11-12 2016-10-26 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
GB2558442B (en) * 2013-12-17 2018-10-24 Kymab Ltd Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
CN106062004A (zh) * 2013-12-17 2016-10-26 科马布有限公司 人靶标
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP2886557A1 (en) * 2013-12-17 2015-06-24 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP2975058A1 (en) * 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
FR3014695A1 (enExample) * 2013-12-17 2015-06-19 Kymab Ltd
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
ES2912183T3 (es) 2013-12-30 2022-05-24 Atreca Inc Análisis de ácidos nucleicos asociados a células individuales utilizando códigos de barras de ácidos nucleicos
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
WO2015200438A1 (en) * 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
US10611850B2 (en) * 2014-07-14 2020-04-07 Amgen Inc. Crystalline antibody formulations
CA2954767A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
DE202015009006U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP4328245A3 (en) 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP2975059A1 (en) * 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
KR20170029613A (ko) 2014-07-16 2017-03-15 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
CA2957258C (en) 2014-08-05 2023-11-07 MabQuest SA Immunological reagents
US20170224816A1 (en) 2014-08-06 2017-08-10 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
EP3194441A1 (en) 2014-09-16 2017-07-26 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
MA54716A (fr) 2014-10-23 2021-11-17 Amgen Inc Réduction de la viscosité de formulations pharmaceutiques
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
CN105461809B (zh) 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
CA2979219A1 (en) * 2015-03-10 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
JP2018516624A (ja) * 2015-04-15 2018-06-28 コンシーヴァルブ エルエルシー 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN105037554B (zh) * 2015-06-12 2019-04-12 成都贝爱特生物科技有限公司 抗人pcsk9抗体的制备及其用途
IL314925A (en) 2015-08-18 2024-10-01 Regeneron Pharma Antibodies against PCSK9 for the treatment of patients with hyperlipidemia undergoing lipoprotein-lowering therapy
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
WO2017106326A1 (en) * 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
WO2017114230A1 (zh) * 2015-12-31 2017-07-06 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
US20200270365A1 (en) 2016-01-05 2020-08-27 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
CA3012075A1 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2017163049A1 (en) 2016-03-21 2017-09-28 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
CN107266575B (zh) * 2016-04-07 2021-12-24 天士力生物医药股份有限公司 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CN107840893B (zh) * 2016-09-20 2022-02-25 信立泰(成都)生物技术有限公司 新型抗-pcsk9抗体
US11111313B2 (en) 2016-09-20 2021-09-07 WuXi Biologics Ireland Limited Anti-PCSK9 antibodies
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
CN108239150A (zh) * 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN110418846A (zh) 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
EP3600082A4 (en) 2017-03-21 2020-09-16 Teleflex Medical Incorporated SURGICAL STAPLE AND STAPLE APPLICATOR
US12023041B2 (en) 2017-03-21 2024-07-02 Teleflex Medical Incorporated Clip applier
WO2018222186A1 (en) * 2017-05-31 2018-12-06 North Carolina Central University Optimization of an active pcsk9 assay
CN107029243A (zh) * 2017-06-08 2017-08-11 厦门大学 一种多肽桥连的双酰腙连接键应用于醛衍生药物的递送
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
JP6913566B2 (ja) * 2017-08-23 2021-08-04 協同油脂株式会社 グリース組成物
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
US11826480B2 (en) 2017-11-03 2023-11-28 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
EP4640703A2 (en) 2017-11-14 2025-10-29 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
US12110342B2 (en) * 2018-01-31 2024-10-08 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
WO2019164929A1 (en) * 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Antibody variable domains targeting cd33, and use thereof
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
CN112166120B (zh) 2018-03-30 2024-09-10 安姆根有限公司 C末端抗体变体
MX2020013155A (es) 2018-06-05 2021-04-29 Anji Pharma Us Llc Composiciones y metodos para tratar la pancreatitis.
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
CN120694710A (zh) 2018-09-26 2025-09-26 泰利福医疗公司 具有稳定构件的施夹器
EA202191058A1 (ru) * 2018-11-16 2021-10-07 Мемориал Слоун Кеттеринг Кэнсер Сентр Антитела против муцина-16 и способы их применения
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CN109776680B (zh) * 2019-01-25 2020-05-12 浙江蓝盾药业有限公司 抗人pcsk9单克隆抗体及其用途
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
EP4640848A2 (en) 2019-05-17 2025-10-29 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
WO2021050989A1 (en) * 2019-09-13 2021-03-18 Duke University Zika antibodies and their use
WO2021058597A1 (en) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject is at risk of developing arterial plaques
GB201913846D0 (en) 2019-09-25 2019-11-06 King S College London Biomarker
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
CA3160071A1 (en) * 2019-11-18 2021-05-27 Ad Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody and use thereof
WO2021105389A1 (en) 2019-11-29 2021-06-03 Kymab Limited Treatment for physiological iron overload
KR20220143005A (ko) * 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
BR112023020152A2 (pt) 2021-03-31 2023-11-14 Cambridge Entpr Ltd Inibidores terapêuticos de sinalização gdf15
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CN113480650B (zh) * 2021-06-30 2022-01-28 徐州医科大学 一种全人源靶向cd276的car-t细胞的制备方法及应用
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023076419A2 (en) * 2021-10-27 2023-05-04 Twist Bioscience Corporation Sars-cov-2 antibodies and methods of use
CN119161484A (zh) 2022-04-25 2024-12-20 武汉大学 抗asgr1单克隆抗体及其应用
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
EP4525991A1 (en) 2022-05-18 2025-03-26 Kymab Limited Uses of anti-icos antibodies
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025036347A1 (zh) * 2023-08-14 2025-02-20 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US896507A (en) 1908-04-06 1908-08-18 Theodore J Asch Sweat-band.
US1063008A (en) 1913-03-15 1913-05-27 William E Budd Vehicle-tire.
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5612114B2 (enExample) * 1974-06-07 1981-03-18
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング　ビーブイ 哺乳動物細胞における相同性組換え
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69233204T2 (de) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JPH07508410A (ja) 1992-06-18 1995-09-21 ジェンファーム　インターナショナル　インコーポレイテッド 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2230759C (en) 1995-08-29 2012-02-21 Kirin Beer Kabushiki Kaisha Chimeric animal and method for producing the same
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
WO1998001100A2 (en) 1996-07-09 1998-01-15 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20080103090A1 (en) * 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
US20060223090A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US7968689B2 (en) * 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20060223088A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US20060246483A1 (en) * 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US20070224663A1 (en) * 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20070055056A1 (en) * 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US20070015696A1 (en) * 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
FR2784749B1 (fr) 1998-10-14 2000-12-29 Instruments Sa Appareil de caracterisation optique de materiau en couche mince
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB2343233A (en) 1998-10-28 2000-05-03 Whitnash Plc Torsional vibration damper.
NL1011069C2 (nl) 1999-01-19 2000-07-20 Well Engineering Partners B V Werkwijze en installatie voor het inbrengen van een buis in een boorgat in de aardbodem.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1514933A1 (en) * 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030119038A1 (en) * 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US20100291099A1 (en) * 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
US7029895B2 (en) * 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20110230392A1 (en) * 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
CA2388617A1 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20020081679A1 (en) * 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
EP1257572A2 (en) 2000-02-07 2002-11-20 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
JP3753917B2 (ja) 2000-03-17 2006-03-08 茨木精機株式会社 包装体の整列搬出方法及びその装置
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
WO2002014358A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Novel secreted proteins and their uses
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
EP1358325A2 (en) * 2000-12-08 2003-11-05 Incyte Genomics, Inc. Protein modification and maintenance molecules
EP1414845A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences SEPARATE HUMAN PROTEINS
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023243A1 (en) * 2001-06-13 2004-02-05 Yue Henry Proteases
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040038242A1 (en) * 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
WO2003076568A2 (en) 2002-02-11 2003-09-18 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JP4999158B2 (ja) * 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
AU2005272912A1 (en) 2004-08-10 2006-02-23 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US20060147945A1 (en) * 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US7682981B2 (en) * 2005-01-27 2010-03-23 Contour Semiconductor, Inc. Topography transfer method with aspect ratio scaling
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CA2637837A1 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EP2021467A4 (en) 2006-05-08 2010-01-20 Adaerata Ltd Partnership CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
SG171676A1 (en) * 2006-05-11 2011-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008042383A1 (en) 2006-10-02 2008-04-10 Armstrong World Industries, Inc. Process for preparing high molecular weight polyesters
WO2008050962A1 (en) * 2006-10-24 2008-05-02 College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
CA2667869A1 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2668131A1 (en) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2667989A1 (en) * 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
JP5086618B2 (ja) * 2006-11-27 2012-11-28 オリンパス株式会社 カプセル型内視鏡
JP2010510807A (ja) 2006-11-27 2010-04-08 アイシス ファーマシューティカルズ， インコーポレーテッド 高コレステロール血症を治療するための方法
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
TW200906439A (en) * 2007-04-13 2009-02-16 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
US8975377B2 (en) 2007-08-13 2015-03-10 Vasgene Therapeutics, Inc Cancer treatment using humanized antibodies that bind to EphB4
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
CN102232088A (zh) * 2007-10-26 2011-11-02 先灵公司 用于治疗脂类和胆固醇疾病的抗pcsk9及方法
EP2245039A4 (en) * 2008-01-31 2012-06-06 Alnylam Pharmaceuticals Inc OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
CA2713935C (en) 2008-02-07 2016-11-01 Schering Corporation Engineered anti-tslpr antibodies
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
WO2009131740A2 (en) 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
DE102008034203B4 (de) * 2008-07-21 2018-04-26 Airbus Helicopters Deutschland GmbH Herstellung von Faserverbundbauteilen mit Formkernen
ES2808660T3 (es) 2008-08-04 2021-03-01 Amgen Inc Proteínas de unión a antígeno para proproteína convertasa subtilisina kexina tipo 9 (PCSK9)
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010068526A1 (en) 2008-12-12 2010-06-17 Merck Sharp & Dohme Corp. Pcsk9 immunoassay
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
US8210622B2 (en) 2009-03-13 2012-07-03 Liberty Hardware Mfg. Corp. Adjustable product display assembly
WO2011028938A1 (en) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
NZ599323A (en) 2009-10-15 2014-06-27 Univ Monash Affinity ligands and methods for protein purification
IN2012DN03824A (enExample) * 2009-10-30 2015-08-28 Merck Sharp & Dohme
US8802827B2 (en) * 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
JP2013509591A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｐｃｓｋ９イムノアッセイ
US20120208208A1 (en) * 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
WO2011061712A1 (en) 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
CN105218674A (zh) * 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
EP3424949A1 (en) * 2010-04-13 2019-01-09 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
CN201712554U (zh) 2010-07-14 2011-01-19 李辉 电动汽车热管理系统
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
CN103328514B (zh) 2010-11-09 2015-12-02 阿尔蒂单抗治疗公司 用于抗原结合的蛋白复合物及其使用方法
US8613308B2 (en) 2010-12-10 2013-12-24 Uop Llc Process for transferring heat or modifying a tube in a heat exchanger
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EP2481758A1 (en) 2011-01-28 2012-08-01 Sanofi Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
HRP20180959T1 (hr) 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
EP2673302A1 (en) 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
CN103717615A (zh) 2011-06-20 2014-04-09 霍夫曼-拉罗奇有限公司 结合pcsk9的多肽及使用方法
HK1202804A1 (en) 2011-07-14 2015-10-09 辉瑞公司 Treatment with anti-pcsk9 antibodies
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
CA2848201C (en) 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
HK1204477A1 (en) 2011-12-20 2015-11-20 阿达拉塔合伙有限公司 Single domain antibodies as inhibitors of pcsk9
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
RU2015101113A (ru) 2012-06-15 2016-08-10 Дженентек, Инк. Антитела против pcsk9, составы, дозы и способы применения
EP2703009A1 (en) 2012-08-31 2014-03-05 Sanofi Combination treatments involving antibodies to human PCSK9
EP2706070A1 (en) 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
JP2016514668A (ja) 2013-03-15 2016-05-23 アムジエン・インコーポレーテツド プロタンパク質コンベルターゼスブチリシンケクシン９型に結合するヒト抗原結合タンパク質
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly
DE102023206495B3 (de) 2023-07-07 2024-11-21 Volkswagen Aktiengesellschaft Integrierter Schaltkreis, Anordnung sowie Verfahren zum Einkoppeln von optischen Signalen in einen integrierten Schaltkreis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
2006年02月， " Expression and localization of PCSK9 in rat hepatic cells", Grozdanov, PN et al，Biochem Cell Biol. 2006 Feb;84(1):80-92. *
2006年11月11日，"Secreted PCSK9 decreases the number of LDL receptors in epatocytes and in livers of parabiotic mice"， Lagace et al，J Clin Invest. 2006 Nov;116(11):2995-3005 *
2006年11月11日，"Secreted PCSK9 decreases the number of LDL receptors in epatocytes and in livers of parabiotic mice"， Lagace et al，J Clin Invest. 2006 Nov;116(11):2995-3005。
2007年08月16日，Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol，Clin Chem. 2007 Oct;53(10):1814-9 *
2007年08月16日，Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol，Clin Chem. 2007 Oct;53(10):1814-9。

Also Published As

Publication number Publication date
CA2696252C (en) 2016-06-14
CN104311665A (zh) 2015-01-28
DK3666797T3 (da) 2023-05-30
HUE028162T2 (en) 2016-12-28
US8563698B2 (en) 2013-10-22
PH12013502285B1 (en) 2024-04-12
NO2016010I1 (no) 2016-06-03
HRP20160494T1 (hr) 2016-06-03
ES2946083T3 (es) 2023-07-12
SG184702A1 (en) 2012-10-30
US8859741B2 (en) 2014-10-14
US20130079501A1 (en) 2013-03-28
DK2215124T3 (en) 2016-05-30
CL2008002495A1 (es) 2009-09-04
JP2010536384A (ja) 2010-12-02
PL2215124T3 (pl) 2016-08-31
AR068011A1 (es) 2009-10-28
IL204013B2 (en) 2025-07-01
CY2016023I1 (el) 2017-04-26
DK2215124T4 (da) 2024-01-29
US8889834B2 (en) 2014-11-18
KR20180035947A (ko) 2018-04-06
US20140235830A1 (en) 2014-08-21
EP2215124A1 (en) 2010-08-11
CN104311666A (zh) 2015-01-28
PE20221507A1 (es) 2022-10-04
US20130079502A1 (en) 2013-03-28
HRP20160494T4 (hr) 2023-10-27
US8981064B2 (en) 2015-03-17
UA127402C2 (uk) 2023-08-16
US9920134B2 (en) 2018-03-20
DE19207796T1 (de) 2022-03-10
IL304868A (en) 2023-10-01
KR20100057070A (ko) 2010-05-28
US20090142352A1 (en) 2009-06-04
BRPI0816117B1 (pt) 2018-12-18
HRP20230503T3 (hr) 2023-09-15
CO6230997A2 (es) 2010-12-20
TWI890005B (zh) 2025-07-11
TN2010000063A1 (en) 2011-09-26
SI2215124T1 (sl) 2016-09-30
US8030457B2 (en) 2011-10-04
US9056915B2 (en) 2015-06-16
CN112415203A (zh) 2021-02-26
KR20170012592A (ko) 2017-02-02
PE20180173A1 (es) 2018-01-22
RS64295B1 (sr) 2023-07-31
NL300818I2 (enExample) 2016-07-14
ES2573258T5 (es) 2024-02-23
US20140357854A1 (en) 2014-12-04
KR20140064962A (ko) 2014-05-28
US8829165B2 (en) 2014-09-09
US20150087819A1 (en) 2015-03-26
US20130245235A1 (en) 2013-09-19
TWI675848B (zh) 2019-11-01
LTC2215124I2 (lt) 2023-04-25
US20120093818A1 (en) 2012-04-19
JOP20080381B1 (ar) 2023-03-28
HK1143824A1 (zh) 2011-01-14
IL273353A (en) 2020-05-31
JP5906333B2 (ja) 2016-04-20
TWI799416B (zh) 2023-04-21
KR20240113594A (ko) 2024-07-22
US20140228547A1 (en) 2014-08-14
JP2014043446A (ja) 2014-03-13
DE202008018562U1 (de) 2015-11-02
US20140228545A1 (en) 2014-08-14
FR16C0025I2 (fr) 2018-06-08
PE20091006A1 (es) 2009-08-14
IL317213A (en) 2025-01-01
MY180102A (en) 2020-11-22
TW200916481A (en) 2009-04-16
TWI441833B (zh) 2014-06-21
TWI675847B (zh) 2019-11-01
LTPA2016021I1 (lt) 2016-06-27
AU2008288791B2 (en) 2014-10-30
IL204013A (en) 2017-07-31
KR20220031734A (ko) 2022-03-11
MY199053A (en) 2023-10-11
PH12013502286A1 (en) 2016-02-22
RS54756B2 (sr) 2024-07-31
KR20210028741A (ko) 2021-03-12
CY2016023I2 (el) 2017-04-26
US20120020975A1 (en) 2012-01-26
JP2018118974A (ja) 2018-08-02
JP2016182114A (ja) 2016-10-20
DE19207796T9 (de) 2023-02-23
LTPA2016025I1 (lt) 2016-09-12
LU93096I2 (fr) 2016-08-01
IL252616B (en) 2020-05-31
US20150031870A1 (en) 2015-01-29
US8883983B2 (en) 2014-11-11
US20120020976A1 (en) 2012-01-26
CA2696252A1 (en) 2009-02-26
US20130085265A1 (en) 2013-04-04
MX2010001921A (es) 2010-03-11
PE20140221A1 (es) 2014-02-21
HUS1600036I1 (hu) 2016-10-28
US20140357850A1 (en) 2014-12-04
EP3202791A1 (en) 2017-08-09
EP2215124B9 (en) 2023-12-27
JP5441905B2 (ja) 2014-03-12
CY2016029I1 (el) 2017-04-26
US20120213797A1 (en) 2012-08-23
PE20140014A1 (es) 2014-01-31
CN112390889A (zh) 2021-02-23
JP6638009B2 (ja) 2020-01-29
MA31978B1 (fr) 2011-01-03
HUS1600029I1 (hu) 2016-09-28
PH12013502285A1 (en) 2016-08-08
MX375117B (es) 2025-03-06
PL2215124T5 (pl) 2023-11-20
BR122018012430B1 (pt) 2019-10-08
ES2573258T3 (es) 2016-06-06
TW201500375A (zh) 2015-01-01
TW201500374A (zh) 2015-01-01
TW201906871A (zh) 2019-02-16
FR16C0025I1 (fr) 2016-07-08
CN104311667A (zh) 2015-01-28
EP2215124B2 (en) 2023-07-19
AU2008288791A1 (en) 2009-02-26
JP5705288B2 (ja) 2015-04-22
US9493576B2 (en) 2016-11-15
US9045547B2 (en) 2015-06-02
ES2917423T3 (es) 2022-07-08
EP3666797A1 (en) 2020-06-17
NO2016015I1 (no) 2016-08-12
PE20131400A1 (es) 2013-12-16
IL273353B1 (en) 2023-09-01
CN101932607A (zh) 2010-12-29
NO2023012I1 (no) 2023-03-20
RS54756B1 (sr) 2016-10-31
US20110027287A1 (en) 2011-02-03
WO2009026558A1 (en) 2009-02-26
JP2023071833A (ja) 2023-05-23
US8871914B2 (en) 2014-10-28
PL3666797T3 (pl) 2023-08-28
US20090326202A1 (en) 2009-12-31
US20140228557A1 (en) 2014-08-14
US20140357852A1 (en) 2014-12-04
SI2215124T2 (sl) 2023-11-30
IL273353B2 (en) 2024-01-01
EA201000356A1 (ru) 2010-08-30
PE20140231A1 (es) 2014-03-08
US20120027765A1 (en) 2012-02-02
JP2020058376A (ja) 2020-04-16
BRPI0816117A2 (pt) 2015-03-10
CY2016029I2 (el) 2017-04-26
CN101932607B (zh) 2014-06-25
US20130058944A1 (en) 2013-03-07
EP2215124B1 (en) 2016-02-24
NZ584101A (en) 2012-09-28
KR101702194B1 (ko) 2017-02-03
US8168762B2 (en) 2012-05-01
JP2015166345A (ja) 2015-09-24
HUE062493T2 (hu) 2023-11-28
FI2215124T4 (fi) 2023-10-10
US20140357853A1 (en) 2014-12-04
SI3666797T1 (sl) 2023-10-30
KR101494932B1 (ko) 2015-02-26
US20130052201A1 (en) 2013-02-28
BRPI0816117B8 (pt) 2021-05-25
MX2020008898A (es) 2020-10-12
BR122018012430B8 (pt) 2021-07-27
TW201500376A (zh) 2015-01-01
TWI675846B (zh) 2019-11-01
KR20200074262A (ko) 2020-06-24
CR11328A (es) 2010-07-12
KR20230080496A (ko) 2023-06-07
US20120251544A1 (en) 2012-10-04
EA032106B1 (ru) 2019-04-30
TW202330625A (zh) 2023-08-01
FI3666797T3 (fi) 2023-05-25
CY1117940T1 (el) 2017-04-26
CN113402611A (zh) 2021-09-17
IL252616A0 (en) 2017-07-31
DK3666797T5 (da) 2024-08-26
LU93180I2 (fr) 2016-10-18
PE20140220A1 (es) 2014-02-21
MY199051A (en) 2023-10-11
PT3666797T (pt) 2023-06-07
SG10201710183TA (en) 2018-01-30
LT3666797T (lt) 2023-08-10
TW201716444A (zh) 2017-05-16
US20140357851A1 (en) 2014-12-04
US20140235831A1 (en) 2014-08-21
CN112409489A (zh) 2021-02-26
EP3666797B1 (en) 2023-05-17
US8871913B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
TWI633122B (zh) 針對前蛋白轉化酶枯草桿菌蛋白酶加工酶９型之抗原結合蛋白
US20130072665A1 (en) Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
HK40031907A (en) Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)